Articles

Sierra Articles

October 2, 2020BioSpaceNews

Sierra Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020

Sierra Oncology, Inc. granted stock options to two new employees, as approved by the Compensation Com... See more »
September 14, 2020MarketScreenerNews

to Present at September Investor Conferences

(marketscreener.com) VANCOUVER, BC, Sept. 14, 2020 /PRNewswire/ - Sierra Oncology, Inc. , a late-stag... See more »
August 6, 2020St Louis Post DispatchNews

2Q Earnings Snapshot

VANCOUVER, British Columbia (AP) - Sierra Oncology, Inc (SRRA) on Thursday reported a loss of $16.5 m... See more »
August 6, 2020PR NewswirePress Release

Sierra Oncology Reports Second Quarter 2020 Results

- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - - Updat... See more »
August 6, 2020PR NewswirePress Release

Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

- Kevin Norrett appointed Chief Business Officer - - William D. Turner appointed Chief Regulatory and... See more »
June 26, 2020Insider MonkeyNews

Hedge Funds In Wait-and-See Mode

June 18, 2020ZacksNews

What Does It Mean for the Stock?

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which... See more »
June 12, 2020MarketScreenerNews

Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

(marketscreener.com) - Data presented at the 25th European Hematology Association Virtual Congress fu... See more »
May 27, 2020MarketScreenerNews

Announces Presentations at Upcoming Investor Conferences

(marketscreener.com) - Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 2... See more »
May 7, 2020PR NewswirePress Release

Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday... See more »
May 7, 2020BioSpaceNews

Sierra Oncology Reports First Quarter 2020 Results

Sierra Oncology, Inc. (SRRA), today reported its financial and operational results for the first quar... See more »
March 12, 2020FierceBiotechNews

Attacking drug-resistant tumors with Sierra's struggling CHK1 blocker

Sierra Oncology deprioritized the development of its CHK1 blocker SRA737 last year, as it steered mos... See more »
December 7, 2019centralchartsPress Release

Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Dire... See more »
December 2, 2019PR NewswirePress Release

Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8... See more »
November 6, 2019PR NewswirePress Release

Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019

- New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients a... See more »
August 7, 2019centralchartsPress Release

Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York

VANCOUVER, Aug. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development co... See more »
June 27, 2019PR NewswirePress Release

Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets

- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Explorin... See more »
June 1, 2019CentralChartsPress Release

Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration

- Sierra to discuss clinical findings and possible next steps for SRA737 at Analyst & Investor Event ... See more »
May 15, 2019PR NewswirePress Release

Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster prese... See more »
Loading interface...
Loading interface...
Loading interface...
Loading interface...